Synthesis and anti-inflammatory activity of some benzimidazole-2-carboxylic acids

Pharmacologyonline

Volumn 1, Issue , 2007, Pages 314-329

  Thakurdesai, Prasad A ^a   Wadodkar, Sudhir G ^b   Chopade, Chandrabhan T ^b  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b RTM NAGPUR UNIVERSITY   (India)

Author keywords

Acute anti inflammatory activity; Benzimidazole 2 carboxylic acids; Carrageenan induced rat paw edema model

Indexed keywords

1 BENZYL BENZIMIDAZOLE ACID; 2 (5 ETHYL 2 PYRIDYL)BENZIMIDAZOLE; 2 (5 NITRO 1H BENZO[D]IMIDAZOL 2 YL)ACETIC ACID; ACETIC ACID DERIVATIVE; ANTIINFLAMMATORY AGENT; BENDAZOL DERIVATIVE; BENZIMIDAZOLE 2 CARBOXYLIC ACID DERIVATIVE; BENZIMIDAZOLE 2 PROPIONIC ACID; BENZIMIDAZOLE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CARRAGEENAN; MEBENDAZOLE; OMEPRAZOLE; PROPIONIC ACID DERIVATIVE; TILOMISOLE; UNCLASSIFIED DRUG; WY 18521;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; PAW EDEMA; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT;

EID: 34248647612     PISSN: None     EISSN: 18278620     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Chan FK. Primer: managing NSAID-induced ulcer complications - balancing gastrointestinal and cardiovascular risks. Nature clinical practice. 2006 Oct;3(10):563-73.
2. Whittle BJ. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol. 2004 Oct 1;500(1-3):427-39.
3. Cryer B. The role of cyclooxygenase selective inhibitors in the gastrointestinal tract. Current gastroenterology reports. 2003 Dec;5(6):453-8.
4. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. The American journal of medicine. 1996 Jul 31;101(1A):25S-32S.
5. Kimmey MB. NSAID, ulcers, and prostaglandins. The Journal of rheumatology. 1992 Nov;36:68-73.
6. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Annals of the rheumatic diseases. 2004 Jul;63(7):759-66.
7. Scherrer RA. Antiinflammatory drugs : Chemistry and Pharmacology In: Scherrer RA, Woodhouse MW, editors. London: Academic press; 1974. p. 119-22.
8. Nicholson RM, Murphy JR, Dearden JR. Hypothetical receptor model for antiinflammatory agents. Journal of Pharmacy and Pharmacology. 1982;34(Suppl):106P.
9. Gund P, Jensen NP. Nonsteroidal antiinflammatory and anti-arthritic drugs. In: Blankley J, editor. Quantitative structure activity relationships of drugs. New York.: Academic press; 1983. p. 285-326.
10. Borne RF. Nonsteroidal antiinflammatory drugs. In: Foye WO, editor. Principles of medicinal chemistry. 5th ed. Philadelphia: Lea & Fabiger,; 1995, p. 535-79.
11. Preston PN. Benzimidazoles. In: Preston PN, editor. Chemistry of heterocyclic compounds: Benzimidazoles. New York: Wiley-Intrescience; 1980. p. 1-281.
12. Cain CK, Reoszkowasky AP. Benzoxazoles, Benzothiazoles and Benzimidazoles. In: Arians EJ, editor. Medicinal Chemistry: Series of monographs. New York: Academic press; 1978. p. 325-57.
13. Hofmann K. Imidazole and it's derivatives. Chemistry of Heterocyclic compounds. New York: Interscience Publishers; 1953. p. 247-324.
14. Tsukamoto G, Yoshino K, Kohno T, Ohtaka H, Kagaya H, Ito K. Synthesis and antiinflammatory activity of some 2-(substituted-pyridinyl)benzimidazoles. J Med Chem. 1980 Jul;23(7):734-8.
15. Ito K, Kagaya H, Satoh I, Tsukamoto G, Nose T. The studies of the mechanism of antiinflammatory action of 2-(5- ethylpyridin-2-yl)benzimidazole (KB-1043). Arzneimittelforschung. 1982;32(2):117-22.
16. Ito K, Kagaya H, Fukuda T, Yoshino K, Nose T. Pharmacological studies of a new non-steroidal antiinflammatory drug: 2- (5-ethylpyridin-2-yl)benzimidazole (KB-1043). Arzneimittelforschung. 1982;32(1):49-55.
17. Gilman SC, Carlson RP, Chang J, Lewis AJ. The antiinflammatory activity of the immunomodulator Wy-18,251 (3-(p- chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid). Agents Actions. 1985;17(1):53-9.
18. Gilman SC, Carlson RP, Lewis AJ. Immunomodulatory activity of Wy-18,251 (3-(p-chlorophenyl) thiazolo[3,2- a]benzimidazole-2-acetic acid). J Immunopharmacol. 1985;7(1):79-98.
19. Lazer ES, Matteo MR, Possanza GJ. Benzimidazole derivatives with atypical antiinflammatory activity. J Med Chem. 1987;30(4):726-9.
20. Taniguchi K, Shigenaga S, Ogahara T, Fujitsu T, Matsuo M. Synthesis and antiinflammatory and analgesic properties of 2-amino-1H-benzimidazole and 1,2-dihydro -2-iminocycloheptimidazole derivatives. Chem Pharm Bull (Tokyo). 1993;41(2):301-9.
21. Boido A, Vazzana I, Sparatore F, Cenicola ML, Donnoli D, Marmo E. Preparation and pharmacological activity of some 1-lupinylbenzimidazoles and 1-lupinylbenzotriazoles. Farmaco. 1991 Jun;46(6):775-88.
22. Da Settimo F, Primofiore G, Da Settimo A, La Motta C, Taliani S, Simorini F, et al. [1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors. J Med Chem. 2001;44(25):4359-69.
23. Vogal AI. A Textbook of Practical Organic Chemistry. 3rd ed. London: ELBS & Longman Ltd; 1975. p. 225-36.
24. Copeland RA, Day AR. The preparation and reactions of 2-Benzimidazole carboxylic acid and 2-Benzimidazoleacetic acid. Journal of American Chemical Society. 1943;65:1072-5.
25. Rastogi R, Sharma S, Iyer RN. Synthesis of benzimidazole-2-carboxamides as potential anti-histaminic agents. Indian Journal of Chemistry. 1979;18B(464-467).
26. Phillips MA. Preparation of benzimidazoles. Journal of Chemical Society. 1928:174-5.
27. Organization for Economic Co-operation and Development. Guidance Document on Acute Oral Toxicity Testing. Paris: Environment Directorate, OECD; 2001.
28. Winter CA, Risley EA, Nuss WG. Carrageenin-induced edema in hind paw of the rats as an assay for anti-inflammatory drugs. Proceedings of the Society for Experimental Biology and Medicine. 1962;111:544-7.
29. Hubert JJ, Bohider NR, Peace KE. Regression analysis. In: Peace KE, editor. Biopharmaceutical Statistics for Drug Development. Basel & New York: Marcel Dekker; 1992. p. 1-20.
30. Lagorce JF, Fatimi J, Lakhdar M, Chabernaud ML, Buxeraud J, Raby C. Synthesis and inhibitory effects of 2-pyridyl-2-thiobenzoxazole and 2-pyridyl-2-thiobenzimidazole derivatives on arachidonic acid metabolism. Arzneimittelforschung. 1995 Nov;45(11):1207-10.
31. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New biology. 1971 Jun 23;231(25):232-5.
32. Vane JR, Botting RM. The mechanism of action of aspirin. Thrombosis research. 2003 Jun 15;110(5-6):255-8.
33. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998 Oct;47 Suppl 2:S78-87.
34. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annual review of pharmacology and toxicology. 1998;38:97-120.
35. Claria J, Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Current pharmaceutical design. 2005;11(26):3431-47.
36. Julemont F, Dogne JM, Pirotte B, de Leval X. Recent development in the field of dual COX/5-LOX inhibitors. Mini reviews in medicinal chemistry. 2004 Aug;4(6):633-8.
37. Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. Faseb J. 1987 Aug;1(2):89-96.
38. Eleni P, Dimitra HL. Review in quantitative structure activity relationships on lipoxygenase inhibitors. Mini reviews in medicinal chemistry. 2003 Aug;3(5):487-99.
39. Ruwart MJ, Nezamis JE, Rush BD, Lancaster C, Davis JP, Nichols NM, et al. Timoprazole is a unique cytoprotective agent in the rat. Digestion. 1984;30(1):33-40.
40. Musser JH, Kubrak DM, Chang J, DiZio SM, Hite M, Hand JM, et al. Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters. J Med Chem. 1987 Feb;30(2):400-5.
41. Skelly MM, Hawkey CJ. COX-LOX inhibition: current evidence for an emerging new therapy. International journal of clinical practice. 2003 May;57(4):301-4.
42. Rainsford KD. The ever-emerging anti-inflammatories. Have there been any real advances? Journal of physiology, Paris. 2001 Jan-Dec;95(1-6):11-9.
43. Rainsford KD. Mechanisms of gastrointestinal damage by NSAIDS. Agents and actions. 1993;44:59-64.
44. Crowther AF, Curd FHS, Davey DG, Stacey CJ. Synthetic antimalerials Part XXXIX: 5(or 6)-Chloro-2-hydroxymethyl benzimidazole. Journal of Chemical Society. 1949;49:1260-71.
45. Chatterjee B. CCCC.-Attempts to find new antimalerials. Part IV. Beta-Benzimidazolylethylamine and beta-5(or 6)-Ethoxybenzimidazolylethylamine. Journal of Chemical Society. 1929:2965-668.
46. James AT, Turner EE. Structure and antimelerial activity. Part IV. Benzimidazoles and mercaptodihydroglyoxalines. Journal of Chemical Society. 1950:1515-9.